Brind.

Market Comparison of Inovio Pharmaceuticals and Synlogic, Inc.

2 reports, 1 independent Updated Mon 00:00
No new developments lately
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

An independent report compared the market profiles of two small-cap healthcare companies, Inovio Pharmaceuticals and Synlogic. The comparison covered institutional and insider ownership, revenue, earnings per share, and valuation. Synlogic had higher earnings but lower revenue than Inovio Pharmaceuticals and was trading at a lower price-to-earnings ratio. Regarding risk, Synlogic had a beta of 0.5, while Inovio Pharmaceuticals had a beta of 1.63.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The report detailed the ownership structures, noting that 63.4% of Synlogic shares were held by institutional investors compared to 26.8% of Inovio Pharmaceuticals shares. The findings provide investors with comparative data on the market risk and market capitalization profiles of both companies.

From themarketsdaily.com

Who's involved

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story